Рациональная фармакотерапия в кардиологии (May 2016)
THE INTERIM EXPERTS’ COUNCIL RESOLUTION ON THE EMPA-REG OUTCOME TRIAL ISSUES
- M. V. Shestakova,
- S. A. Boytsov,
- O. M. Drapkina,
- T. Yu. Demidova,
- H. Drexel,
- M. B. Antsiferov,
- N. A. Petunina,
- N. A. Chernikova,
- V. Yu. Kalashnikov,
- T. P. Bardymova,
- V. K. Protasov,
- A. Yu. Babenko,
- L. A. Ruyatkina,
- V. V. Klimontov,
- V. V. Salukhov,
- V. V. Fadeev,
- Yu. A. Karpov
Affiliations
- M. V. Shestakova
- Institute of Diabetes, Endocrinology Research Center, Moscow
- S. A. Boytsov
- State Research Centre for Preventive Medicine, Moscow
- O. M. Drapkina
- State Research Centre for Preventive Medicine, Moscow
- T. Yu. Demidova
- Russian Medical Academy of Postgraduate Education, Moscow
- H. Drexel
- Vorarlberg Institute for Vascular Investigation and Treatment,Feldkirch
- M. B. Antsiferov
- Endocrinology Clinic of Moscow, Moscow
- N. A. Petunina
- I.M. Sechenov First Moscow State Medical University, Moscow
- N. A. Chernikova
- Russian Medical Academy of Postgraduate Education, Moscow
- V. Yu. Kalashnikov
- Institute of Diabetes, Endocrinology Research Center, Moscow
- T. P. Bardymova
- Irkutsk State Medical Academy of Postgraduate Education, Irkutsk
- V. K. Protasov
- Irkutsk State Medical Academy of Postgraduate Education, Irkutsk
- A. Yu. Babenko
- Institute of Endocrinology, V.A. Almazov Northwestern Federal Medical Research Center, St. Petersburg
- L. A. Ruyatkina
- Novosibirsk State Medical University, Novosibirsk
- V. V. Klimontov
- Novosibirsk State Medical University, Novosibirsk
- V. V. Salukhov
- S.M. Kirov Military Medical Academy, St. Petersburg
- V. V. Fadeev
- Institute of Diabetes, Endocrinology Research Center, Moscow; I.M. Sechenov First Moscow State Medical University, Moscow
- Yu. A. Karpov
- A.L. Myasnikov Institute of Clinical Cardiology, Russian Cardiology Research and Production Complex, Moscow
- DOI
- https://doi.org/10.20996/1819-6446-2016-12-2-186-190
- Journal volume & issue
-
Vol. 12,
no. 2
pp. 186 – 190
Abstract
The interdisciplinary interim experts’ council on March 3, 2016 in Moscow have considered the EMPA-REG OUTCOME trial results and suggested a number of propositions and recommendations on further empagliflozin’s cardiovascular effects investigation and its clinical application in patients with type 2 diabetes at high cardiovascular risk.
Keywords
- empagliflozin
- type 2 diabetes mellitus
- cardiovascular morbidity and mortality
- empa-reg outcome trial
